Search clinical trials for: Sorafenib (BAY43-9006)

Total 1117 results

Johannes Kepler University of Linz

Recruiting

Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography

Macular Degeneration | Diabetic Retinopathy | Retinal Disease

Austria
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
CStone Pharmaceuticals

Recruiting

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Samyang Biopharmaceuticals Corporation
Seoul National University Hospital

Completed

Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers

Healthy, Male

Korea, Republic of
Hamid Sayar
Bayer; Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.

Completed

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype

Acute Myeloid Leukemia

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

Sorafenib and Dacarbazine in Soft Tissue Sarcoma

Sarcoma | Leiomyosarcoma | Malignant Peripheral Nerve Sheath Tumor | Synovial Sarcoma

United States
GERCOR - Multidisciplinary Oncology Cooperative...

Unknown

Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery

Liver Cancer

France
Centre Hospitalier Universitaire Dijon

Completed

Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma

Child-Pugh A Hepatocellular Carcinoma

France
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Singapore General Hospital
National Cancer Centre, Singapore; National Medical Research Council (NMRC)... and other collaborators

Unknown

Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) (SIRveNIB)

Hepatocellular Carcinoma

Taiwan, Korea, Republic of, Malaysia, New Zealand, Philippines, Singapore, China, Thailand, Brunei Darussalam, Indonesia, Mongolia, Myanmar
Bayer

Active, not recruiting

A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment (RegoSeq)

Metastatic Colorectal Cancer

Spain, Italy, France
Lahey Clinic

Withdrawn

Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Virginia Commonwealth University
Eli Lilly and Company; Bayer

Terminated

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Recurrent Breast Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The First Affiliated Hospital of Nanchang University; Guangzhou First People... and other collaborators

Recruiting

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children (SCCLG-M5)

Leukemia, Monocytic, Acute | Pediatric AML

China
Henan Cancer Hospital

Not yet recruiting

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult Man

Healthy Male Adult

China
Institut du Cancer de Montpellier - Val d'Aurelle
Bayer

Completed

Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation (NEXIRI)

Metastatic Colorectal Cancer

France
Duke University
Bayer; Schering-Plough

Completed

Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

Recurrent Glioblastoma Multiforme

United States
Fudan University

Unknown

Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

Colorectal Neoplasms

China
Zhejiang Haichang Biotech Co., Ltd.

Not yet recruiting

Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)
University of Magdeburg
Bayer; Sirtex Medical

Completed

Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer (SORAMIC)

Hepatocellular Carcinoma

Germany
Sanofi

Withdrawn

Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients (SECOX)

Hepatic Neoplasm Malignant
Italian Trial in Medical Oncology

Completed

Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer (P1)

Prostate Cancer

Italy
Sarepta Therapeutics, Inc.

Active, not recruiting

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Limb-Girdle Muscular Dystrophy, Type 2E

United States
Sanofi

Terminated

Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Liver Carcinoma

France
M.D. Anderson Cancer Center
Bayer

Completed

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
St. Jude Children's Research Hospital

Completed

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Leukemia | Refractory Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Stephen Chan Lam

Recruiting

CXD101 in Immunotherapy-related Liver Cancer

HCC

Hong Kong
University of California, San Francisco
Novartis

Completed

Sorafenib and RAD001 Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Hospices Civils de Lyon

Unknown

EVESOR: a Phase 1 Trial of Everolimus and Sorafenib (EVESOR)

Metastatic or Locally Advanced Solid Tumors

France
Bayer

Terminated

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin Melanoma

United States
Huahui Health

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Hepatitis B

Australia
Arixa Pharmaceuticals

Unknown

A Single Ascending Dose Study of AV-006 in Healthy Subjects

Bacterial Infections

Australia
University Hospital Tuebingen
Haag-Streit AG

Completed

Validation of the GATE Software (ValGATE)

Visual Field Defects

Germany
Hoffmann-La Roche

Completed

A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Singapore
The University of Hong Kong

Unknown

Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma (SECOX)

Advanced Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma

China
Bayer

Completed

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)

Gastrointestinal Stromal Tumors

Belgium, Canada, Spain, United States, Finland, Korea, Republic of, Austria, United Kingdom, Italy, China, Israel, France, Poland, Germany, Netherlands, Japan, Singapore
Abramson Cancer Center of the University of Pennsylvania
Sanofi; Bayer

Completed

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Bayer

Terminated

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
St. Jude Children's Research Hospital
Ohio State University; Arog Pharmaceuticals, Inc.

Completed

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

Acute Myeloid Leukemia

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

Advanced Solid Tumors | Pharmacokinetics of 14C-OSI-906

United States
M.D. Anderson Cancer Center
Sabinsa Corporation

Withdrawn

Study of Curcumin, Vorinostat, and Sorafenib

Advanced Cancers
National Cancer Institute (NCI)

Completed

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

Glioblastoma | Brain Tumor | Anaplastic Glioma

United States
Asan Medical Center
Bayer

Completed

Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE

Effects of Chemotherapy | Malignant Neoplasm of Stomach

Korea, Republic of
King's College Hospital NHS Trust

Completed

Randomized Study of Pessary Versus Standard Management in Women With Increased Chance of Premature Birth

Preterm Birth

United Kingdom, Hong Kong, Chile, Spain, Slovenia, Colombia, Austria, Brazil, Germany, India, Italy, Portugal
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Melanoma (Skin)

United States
SCRI Development Innovations, LLC
Bristol-Myers Squibb; Bayer

Completed

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

Metastatic Breast Cancer

United States

Search clinical trials for: Sorafenib (BAY43-9006)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations